Analysts Set Zura Bio Limited (NASDAQ:ZURA) Price Target at $15.80

Shares of Zura Bio Limited (NASDAQ:ZURA) have been given a consensus recommendation of “Buy” by the seven research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $15.80.

Several equities analysts recently commented on ZURA shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. HC Wainwright restated a “neutral” rating and set a $5.00 price target on shares of Zura Bio in a research report on Tuesday, December 24th. Leerink Partners initiated coverage on Zura Bio in a research report on Monday, November 4th. They issued an “outperform” rating and a $15.00 price objective on the stock. Leerink Partnrs upgraded Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th. Finally, Chardan Capital lowered their price target on Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, November 8th.

Insider Activity at Zura Bio

In other news, Director Parvinder Thiara sold 1,001,633 shares of the company’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $2.73, for a total value of $2,734,458.09. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 22.10% of the stock is owned by insiders.

Institutional Trading of Zura Bio

Several hedge funds and other institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC bought a new stake in shares of Zura Bio in the 2nd quarter worth approximately $43,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Zura Bio in the third quarter worth $46,000. SG Americas Securities LLC boosted its position in Zura Bio by 51.6% during the fourth quarter. SG Americas Securities LLC now owns 23,005 shares of the company’s stock valued at $58,000 after buying an additional 7,828 shares during the period. Renaissance Technologies LLC grew its stake in shares of Zura Bio by 51.3% during the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after buying an additional 5,900 shares during the last quarter. Finally, Valence8 US LP purchased a new position in shares of Zura Bio in the third quarter worth about $71,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Zura Bio Stock Performance

NASDAQ:ZURA opened at $1.72 on Friday. Zura Bio has a 1 year low of $1.67 and a 1 year high of $6.35. The stock’s fifty day moving average price is $2.45 and its two-hundred day moving average price is $3.44.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.12). On average, analysts expect that Zura Bio will post -0.65 EPS for the current year.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.